[HTML][HTML] Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional …
C McCabe, H Wright, K Polson, AJ Wagner - Orphanet Journal of Rare …, 2023 - Springer
Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
Dosing recommendation based on the effects of different meal types on pexidartinib pharmacokinetics in healthy subjects: implementation of model‐informed drug …
H Zahir, O Yin, C Hsu, AJ Wagner… - Clinical …, 2023 - Wiley Online Library
Pexidartinib, an oral small molecule inhibitor of the colony‐stimulating factor 1 receptor, is
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …
Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor
H Gelderblom, M de Sande - Future Oncology, 2020 - Taylor & Francis
Pexidartinib is an orally administered small molecule tyrosine kinase inhibitor. Phase III
ENLIVEN study results provided clinical evidence for US FDA approval for treatment of adult …
ENLIVEN study results provided clinical evidence for US FDA approval for treatment of adult …
[HTML][HTML] Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - Springer
Abstract Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
Pexidartinib long‐term hepatic safety profile in patients with tenosynovial giant cell tumors
JH Lewis, H Gelderblom, M Sande, S Stacchiotti… - The …, 2021 - academic.oup.com
Background Pexidartinib is approved in the US for tenosynovial giant cell tumors (TGCTs).
Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs …
Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs …
Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
O Yin, H Zahir, J French, D Polhamus… - CPT …, 2021 - Wiley Online Library
This analysis was conducted to assess exposure–response relationships for efficacy and
safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed …
safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed …
[HTML][HTML] Pexidartinib: first approval
YN Lamb - Drugs, 2019 - Springer
Pexidartinib (TURALIO™) is an orally administered small molecule tyrosine kinase inhibitor
with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto …
with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto …
Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure
S Nakayama, V Lukacova, S Tanabe… - Clinical …, 2024 - Wiley Online Library
Pexidartinib is a systemic treatment for patients with tenosynovial giant cell tumor not
amenable to surgery. Oral absorption of pexidartinib is affected by food; administration with …
amenable to surgery. Oral absorption of pexidartinib is affected by food; administration with …
ENLIVEN study: pexidartinib for tenosynovial giant cell tumor (TGCT)
W Tap - Future Oncology, 2020 - Taylor & Francis
Pexidartinib is the first approved medication in the USA for people with tenosynovial giant
cell tumor (TGCT). The drug was approved based on the ENLIVEN study, which looked at …
cell tumor (TGCT). The drug was approved based on the ENLIVEN study, which looked at …
[HTML][HTML] Pexidartinib (TURALIO™): The first FDA-indicated systemic treatment for tenosynovial giant cell tumor
S Monestime, D Lazaridis - Drugs in R&D, 2020 - Springer
Tenosynovial giant cell tumor is a rare proliferative tumor that arises from the synovium,
bursae, or tendon sheaths due to an overproduction of colony-stimulating factor 1 …
bursae, or tendon sheaths due to an overproduction of colony-stimulating factor 1 …